TVRD Stock Analysis: Buy, Sell, or Hold?
TVRD - Tvardi Therapeutics, Inc. Common Stock
$2.02
-0.08 (-3.81%)
▼
5d:
-20.47%
30d:
+0.0%
90d:
-35.67%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Get Alerted When TVRD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TVRD is down 20.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TVRD is down 20.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TVRD is currently trading at $2.02, which is considered slightly low relative to its 30-day fair value range of $1.93 to $3.39.
Technical Outlook: Technically, TVRD is in a downtrend. The price is currently testing key support at $1.99. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Implied Volatility is high (93th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $9.75 (+364.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TVRD is in a downtrend. The price is currently testing key support at $1.99. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Implied Volatility is high (93th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $9.75 (+364.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.93 -
$3.39
Company Quality Score
48/100
(HOLD)
Options IV Signal
93th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
61.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 93th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.8%)
- BULLISH: Trading 364.3% below Wall St target ($9.75)
- WARNING: Recommendation downgraded due to -20.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.93 -
$3.39
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.90
(44.4%)
Support & Resistance Levels
Support Level
$1.99
Resistance Level
$3.10
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.77
Wall Street Target
$9.75
(+364.3%)
Share & Embed Analysis
Last updated: August 04, 2026 3:47 AM ET
Data refreshes hourly during market hours. Next update: 4:47 AM
Data refreshes hourly during market hours. Next update: 4:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TVRD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 46 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$15 | 54 HOLD |